CA AB1990

Prohibits sale or distribution of compounded weight loss medications (GLP-1 receptor agonists like semaglutide) unless the compounder verifies bulk drug substances are pharmaceutical grade, accompanied by valid certificates of analysis, and sourced from FDA-registered and inspected facilities

Requires compounders to conduct quality control testing on bulk drug substances before use and on finished batches before release, documenting identity, content, and any impurities exceeding 0.1%

Imposes penalties of $1,000 per dose for illegally compounded drugs sold plus mandatory license revocation for violations

Mandates that advertisements for compounded medications disclose side effects, include a statement that the product is not FDA-approved, and contain no unsubstantiated claims about safety or efficacy

Requires retention of all bulk drug substance acquisition and testing records for at least 2 years after expiration of the last drug lot, with records to be furnished to the Board of Pharmacy within one business day upon request